
UPDATE: On April 13, the FDA and CDC recommended that use of Johnson & Johnson’s COVID-19 vaccine be suspended after six women developed serious blood clots after receiving a dose, one of whom died. The CDC will “review these cases and assess their potential significance,” the agencies said in a joint statement. While the cases amounted to less than one per million vaccinations, they resembled similar blood-clot events suffered by recipients of the vaccine made by AstraZeneca, which uses a similar adenovirus vector.
As an object, it’s not much: an inch and a half of glass with a stopper and some liquid inside. But a thimbleful of the stuff has amazing power — the ability to liberate us from our yearlong collective trauma. The fact that it’s available, scarcely a year after the start of a pandemic, is both an industrial miracle and a freakish stroke of luck; a decade ago, technology did not exist that could bring vaccines so quickly to the public’s arms.
Pfizer and Moderna crossed the finish line first, neck and neck, in December. The third and most recently approved vaccine was from Johnson & Johnson. The J&J vaccine holds some crucial advantages: Only one dose is required rather than two, and while the other approved vaccines expire 30 days after thawing, Johnson & Johnson’s lasts three months, making it easier to distribute in countries that lack an advanced cold chain. The story of the vaccine’s path from development to mass distribution is a lesson in the power of the global capitalist system — the network of corporations and supply chains that, though it can suffocate and disempower us as individuals, can also summon forth immense material and intellectual resources and deploy them for the greater good.
From the start, J&J struggled to catch a break. The pharmaceutical giant played it safe during development and lost crucial time, failed to get FDA approval for parts of its U.S. production chain, missed several delivery targets, and wound up with a vaccine that underperformed its rivals in clinical trials. Then, another obstacle: Last week, the New York Timesrevealed that the new batch J&J had pledged would be delayed even further, after a mix-up at a subcontractor’s production facility ruined 15 million doses. The Biden administration has since directed J&J to take over every aspect of vaccine production at the plant.
The setback was significant, but not fatal. The facility where the mix-up occurred was part of a production process that relies on a precise orchestration of timing, engineering, and logistical expertise across multiple continents, which makes it vulnerable to bad luck and human error. But the system is also resilient: When the batch of J&J doses was compromised, alternative supply lines were available to compensate for the failure. Here is how that entire tempestuous journey unfolded — the breakthroughs, the setbacks, and the way the pieces came together to bring vaccines to millions of arms. Continue reading New York: The Story of One Dose